Utah pilot program for AI prescription refills
Utah’s Medical Licensing Board has formally called for the suspension of a state pilot program that allows an artificial intelligence system to assist with prescription refills, citing concerns about patient safety, clinical oversight, and the lack of prior consultation with medical regulators. The program, launched through Utah’s regulatory “sandbox,” enables AI to process renewals for certain previously prescribed medications—typically for chronic conditions—while incorporating phased levels of physician review. Board members argue that prescription management inherently requires individualized clinical judgment, including monitoring for side effects, drug interactions, and treatment effectiveness, and warn that bypassing traditional physician-led evaluation could place patients at risk. State officials have defended the initiative as a controlled and closely monitored experiment designed to expand access and evaluate emerging technologies, noting that safeguards such as physician involvement and limitations on eligible medications are in place. The dispute highlights broader regulatory tensions around integrating AI into clinical decision-making, including questions of authority, oversight, and how existing licensure frameworks should adapt to new models of care delivery.